Announced Date: 2025-09-03 (September 3, 2024)<\/p>\n\n\n\n
Asset Name: Four siRNA programs\u00a0<\/p>\n\n\n\n
Licensor: Shanghai Argo Biopharmaceutical (China)<\/p>\n\n\n\n
Licensee (Buyer): Novartis Pharma<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Scope of Authority:<\/p>\n\n\n\n
An option granted to Novartis to license ex-China\u00a0rights to <\/p>\n\n\n\n
two discovery-stage next generation molecule<\/strong>s for the treatment of severe hypertriglyceridemia (sHTG) and mixed dyslipidemia\uff1b(target may APOC3)<\/p>\n\n\n\n .<\/p>\n\n\n\n and a right of first negotiation to BW-00112 (ANGPTL3)<\/strong>, which is currently in Phase II in the U.S. and\u00a0China, following a combination trial conducted by Argo.<\/p>\n\n\n\n .<\/p>\n\n\n\n License with reciprocal options to share in Profit & Loss (P&L) in the U.S. and China for an additional hepatic-delivered siRNA candidate<\/strong> currently in IND-enabling studies and expected to commence a multi-territorial Phase I in 2026. Novartis to receive an ex-China license to the molecule along with a P&L option in China while Argo to receive a P&L option in the U.S.<\/p>\n\n\n\n .<\/p>\n\n\n\n .<\/p>\n\n\n\n Payment Detail:<\/p>\n\n\n\n Argo will receive an upfront payment of $160 million\uff0c<\/p>\n\n\n\n Eligible to receive potential milestone and option payments of a combined potential value of up to $5.2 billion, <\/p>\n\n\n\n As well as tiered royalties on commercial sales.<\/p>\n\n\n\n In addition, Novartis has expressed its non-binding intention to participate in Argo’s next round of equity financing.<\/p>\n\n\n\n <\/p>\n\n\n\n .<\/p>\n\n\n\n Link:<\/p>\n\n\n\n